Back to Search Start Over

Peroxisome proliferator activated receptor-γ ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells.

Authors :
Jiajun Liu
Huiling Lu
Renwei Huang
Dongjun Lin
Xiangyuan Wu
Qu Lin
Xinyao Wu
Jing Zheng
Xianglin Pan
Jun Peng
Yuqin Song
Maohong Zhang
Ming Hou
Feng Chen
Source :
Cancer Chemotherapy & Pharmacology; Oct2005, Vol. 56 Issue 4, p400-408, 9p
Publication Year :
2005

Abstract

Peroxisome proliferator-activated receptor-gamma (PPAR-γ) is one of the best characterized nuclear hormone receptors (NHRs) in the superfamily of ligand-activated transcriptional factors. PPAR-γ ligands have recently been demonstrated to affect proliferation, differentiation and apoptosis of different cell types. The present study was undertaken to investigate PPAR-γ ligands induced cell growth inhibition and its influence on matrix metalloproteinase MMP-9 and MMP-2 activities on leukemia K562 and HL-60 cells in vitro. The results revealed that PPAR-γ expression was detectable in the two kinds of leukemia cells; Both 15-deoxy-delta(12,14)-prostaglandin J2(15d-PGJ2) and troglitazone (TGZ) have significant growth inhibition effects on these two kinds of leukemia cells. These two PPAR-γ ligands could inhibit the leukemic cell adhesion to the extracellular matrix (ECM) proteins and the invasion through matrigel matrix. The expressions of MMP-9 and MMP-2 as well as their gelatinolytic activities in both HL-60 and K562 cells were inhibited by 15d-PGJ2 and TGZ significantly. We therefore conclude that PPAR-γ ligands 15d-PGJ2 and TGZ have significant growth inhibition effects on myeloid leukemia cells in vitro, and that PPAR-γ ligands can inhibit K562 and HL-60 cell adhesion to and invasion through ECM as well as downregulate MMP-9 and MMP-2 expressions. The data suggest that PPAR-γ ligands may serve as potential anti-leukemia reagents. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03445704
Volume :
56
Issue :
4
Database :
Complementary Index
Journal :
Cancer Chemotherapy & Pharmacology
Publication Type :
Academic Journal
Accession number :
17743134
Full Text :
https://doi.org/10.1007/s00280-005-1029-9